IOL Advances

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets.

According to the company, the center, which officially opens on Thursday, September 26, will serve as a hub for hands-on training and education in lens-based vision correction.

The device features real-time feedback and other features, allowing residents to hone their skills and expand options for practicing one of the most needed procedures in the country.

The Summit will feature 18+ course hours and an extensive resource library to support practice adoption of AT IOLs

A team of 14 eyecare professionals made the recent trip including faculty from the Loyola Medicine Department of Ophthalmology and faculty and residents from Cook County Health, Northwestern Medicine, Wills Eye Hospital in Philadelphia, the University of Toledo College of Medicine and Champlain Ophthalmology in Bethesda, Maryland.

According to the company, its combined vitreoretinal-cataract system and standalone cataract system are cleared for use in the United States.

ZEPTOLink will be introduced at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Diego.

The latest IOLs offer an improvement in stray light performance and enhanced contrast.

Survey participants were asked to enumerate the signs, symptoms, and complaints, the preoperative visual acuities; complications requiring removal or exchange; and secondary interventions.

At the American Academy of Ophthalmology in Chicago, Johnson & Johnson Vision is spotlighting the Tecnis Symfony OptiBlue IOL, its presbyopia-correcting intraocular lens (PC-IOL) powered by InteliLight technology.

According to investigators, halos are the most common complaint for patients who received an implantable collamer lens to address myopia.

Beginning in the 1970s, James J. Salz, MD, was part of a group of ophthalmologists who first inserted intraocular lens implants during cataract surgery.

The EVO/EVO+ Visian Implantable Collamer Lens provides visual freedom independent of contact lenses and glasses.

The company will begin commercialization of the IC-8 small aperture IOL, used for cataract patients, upon successful completion of the manufacturing facility inspections and receipt of an official approval order from the FDA, which the company estimates in Q2 2022.

The approval will allow LensGen to move forward with the IDE pivotal trial with the ultimate goal of seeking premarket approval in the United States.

Lens combines diffractive multifocal and extended depth-of-focus properties.

“Real talk” on new devices gives surgeons, patients decision-making insights

Sustained-release option is deposited directly into the lenticular capsule.

Lens an option for complicated eyes, astigmatism, monovision candidates.

Early experience with next-generation lens engenders positive perception.

Trifocal IOLs can, if implanted with caution, be suitable for patients with keratoconus.

Eric Donnenfeld, MD, presents results of the year-long Grail Study demonstrating the safety and performance of the Juvene IOL from LensGen Inc.

Physician offers practical advice for the use of systems.

Holographic technology offers after-surgery glimpse for surgeons, patients.